12.79

2.52% -0.365

Enanta Pharmaceuticals Inc (ENTA)

Overview News Price History Option Chain Financials Discussions Forecast

Enanta Pharmaceuticals Inc stock is traded at $12.79, with a volume of 185.06K. It is down -2.52% in the last 24 hours and down -6.64% over the past month. Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Previous Close:

$13.16

Open:

$13.13

24h Volume:

185.06K

Relative Volume:

0.90

Market Cap:

$372.66M

Revenue:

$69.21M

Net Income/Loss:

$-61.98M

P/E Ratio:

-4.9312

EPS:

-2.5947

Net Cash Flow:

$-9.61M

1W Performance:

-7.11%

1M Performance:

-6.64%

6M Performance:

-7.45%

1Y Performance:

+60.35%

1-Day Range:

$12.59

$13.32

1-Week Range:

$12.59

$13.98

52-Week Range:

$7.05

$17.15

Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile

Name

Enanta Pharmaceuticals Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

617 607 0800

Address

4 KINGSBURY AVENUE, WATERTOWN, MA

Employee

120

Twitter

@EnantaPharma

Next Earnings Date

2026-08-10

Latest SEC Filings

ENTA's Discussions on Twitter

Compare ENTA vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ENTA Enanta Pharmaceuticals Inc	12.79	383.29M	69.21M	-61.98M	-9.61M	-2.5947
VRTX Vertex Pharmaceuticals Inc	515.76	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.53	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	990.93	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	212.00	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.63	39.31B	5.76B	514.49M	1.10B	4.4813

Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-26-26	Initiated	Rodman & Renshaw	Buy
Nov-14-25	Initiated	JP Morgan	Overweight
Oct-01-25	Upgrade	Jefferies	Hold → Buy
Jul-28-25	Resumed	H.C. Wainwright	Buy
Aug-09-23	Downgrade	JP Morgan	Neutral → Underweight
Aug-08-23	Downgrade	Jefferies	Buy → Hold
Dec-09-22	Initiated	H.C. Wainwright	Buy
Jul-06-22	Upgrade	Evercore ISI	In-line → Outperform
Jun-01-22	Upgrade	Evercore ISI	Underperform → In-line
Oct-07-21	Initiated	Jefferies	Buy
Sep-09-21	Initiated	SVB Leerink	Mkt Perform
Jan-29-21	Upgrade	JP Morgan	Underweight → Neutral
Nov-24-20	Initiated	Evercore ISI	Underperform
Aug-28-20	Resumed	ROTH Capital	Buy
Aug-26-20	Initiated	Piper Sandler	Overweight
Jul-27-20	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Mar-17-20	Upgrade	Robert W. Baird	Neutral → Outperform
Nov-22-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-26-19	Downgrade	JP Morgan	Neutral → Underweight
May-24-19	Initiated	Wolfe Research	Outperform
Apr-23-19	Upgrade	Berenberg	Hold → Buy
Dec-13-18	Initiated	Berenberg	Hold
Jun-06-18	Initiated	ROTH Capital	Buy
Feb-08-18	Downgrade	JP Morgan	Overweight → Neutral
Jan-02-18	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-21-17	Reiterated	RBC Capital Mkts	Outperform
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Jul-11-17	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Apr-28-16	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Feb-09-16	Reiterated	Barclays	Underweight
Oct-23-15	Downgrade	Barclays	Equal Weight → Underweight
Oct-23-15	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform

View All

Enanta Pharmaceuticals Inc Stock (ENTA) Latest News

Aug 14, 2026

Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Share Price, ENTA Stock News, ENTA Share Price & Updates - kalkine.com.au

Aug 14, 2026

Aug 12, 2026

Enanta Pharmaceuticals (ENTA) Stock Faces Revenue Slip And Wider Losses - Sahm

Aug 12, 2026

Aug 11, 2026

H.C. Wainwright Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $20 - Moomoo

Aug 11, 2026

Aug 10, 2026

Enanta Pharma reports $19.5 million Q3 loss, advances RSV pipeline - scanx.trade

Aug 10, 2026

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates - NewsBreak: Local News & Alerts

Aug 10, 2026

Is Enanta Pharmaceuticals (ENTA) Overvalued After Q3 Earnings Mi - GuruFocus

Aug 10, 2026

Enanta Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 10, 2026

Enanta Pharma misses Q3 estimates on lower royalty revenue By Investing.com - Investing.com Canada

Aug 10, 2026

Enanta Fiscal Q3 2026 Earnings: Higher Royalty-Related Interest Expense Widens Net Loss - TradingKey

Aug 10, 2026

Enanta Pharma misses Q3 estimates on lower royalty revenue - Investing.com

Aug 10, 2026

Enanta Pharmaceuticals (NASDAQ:ENTA) Posts Earnings Results, Misses Expectations By $0.16 EPS - MarketBeat

Aug 10, 2026

Enanta Pharmaceuticals reports Q3 loss; revenue $14.4M, cash and securities $211.5M - TradingView

Aug 10, 2026

Enanta Pharma On Track to File IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select MRGPRX2 Development Candidate, in 2H >ENTA - Moomoo

Aug 10, 2026

Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot - AOL.com

Aug 10, 2026

Press Release: Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Third Quarter Ended June 30, 2026 - Moomoo

Aug 10, 2026

Aug 07, 2026

Enanta Pharmaceuticals Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView

Aug 07, 2026

Enanta Pharmaceuticals (ENTA) Climbs 3.2% as Shares Test Key Resistance at $14.46Market Profile - dars.gov.et

Aug 07, 2026

Aug 06, 2026

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Aug 06, 2026

(ENTA) Risk Channels and Responsive Allocation - Stock Traders Daily

Aug 06, 2026

Aug 03, 2026

Enanta Pharmaceuticals (ENTA) Expected to Post Quarterly Earnings on Monday - MarketBeat

Aug 03, 2026

Jul 30, 2026